Fauci Calls Data from Gilead Coronavirus Drug Trial That Included UAB ‘Good News’

By Michelle Fay Cortez, Naomi Kresge and Justin Sink
Bloomberg

The U.S. government’s top infectious disease expert said that early results of a closely watched clinical trial offered “quite good news” regarding a potential COVID-19 therapy made by the biotechnology company Gilead Sciences Inc.

Anthony Fauci, the head of the National Institute of Allergy and Infectious Diseases, which is conducting the study, said at a White House meeting with President Donald Trump and Louisiana Gov. John Bel Edwards that the trial showed a significant positive effect in treating the virus.

Early Wednesday morning, Gilead issued a news release saying it had become aware of results from the NIAID trial showing its experimental drug remdesivir helped patients recover more quickly than standard care, suggesting it could become the first effective treatment for an illness that has turned modern life inside out.

Please CLICK HERE to visit the Alabama NewsCenter website to see this article in its entirety and any other images or videos that go with the article.

Category: ALL POSTS, Partner News Stories